Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study.

Alagoz O, Hajjar A, Chootipongchaivat S, van Ravesteyn NT, Yeh JM, Ergun MA, de Koning HJ, Chicoine B, Martin B.

J Gen Intern Med. 2019 Nov;34(11):2374-2381. doi: 10.1007/s11606-019-05182-5. Epub 2019 Aug 5.

PMID:
31385214
2.

A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries.

Turnbull E, Priaulx J, van Ravesteyn NT, Heinävaara S, Siljander I, Senore C, Segnan N, Vokó Z, Hagymásy J, Jarm K, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1198-1205. doi: 10.1016/j.healthpol.2018.08.003. Epub 2018 Aug 24.

PMID:
30195444
3.

Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M.

Med Decis Making. 2018 Apr;38(1_suppl):112S-125S. doi: 10.1177/0272989X17743244.

4.

Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.

van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):54S-65S. doi: 10.1177/0272989X17711928.

5.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

6.

Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekjær H, Schechter CB, Alagoz O, Huang X, Weaver DL, Burnside ES, Punglia RS, de Koning HJ, Lee SJ.

Med Decis Making. 2018 Apr;38(1_suppl):126S-139S. doi: 10.1177/0272989X17729358.

7.

Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.

Sankatsing VDV, Fracheboud J, de Munck L, Broeders MJM, van Ravesteyn NT, Heijnsdijk EAM, Verbeek ALM, Otten JDM, Pijnappel RM, Siesling S, de Koning HJ; National Evaluation Team for Breast cancer screening, NETB.

BMC Cancer. 2018 Mar 5;18(1):256. doi: 10.1186/s12885-018-4122-2.

8.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

9.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

10.

Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology.

Ripping TM, Ten Haaf K, Verbeek ALM, van Ravesteyn NT, Broeders MJM.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx060. Review.

PMID:
29117353
11.

Authors' reply to: "Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands".

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ.

Int J Cancer. 2017 Oct 15;141(8):1709-1710. doi: 10.1002/ijc.30873. Epub 2017 Jul 21. No abstract available.

12.

The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, van Luijt PA, Fracheboud J, den Heeten GJ, Broeders MJM, de Koning HJ.

Int J Cancer. 2017 Aug 15;141(4):671-677. doi: 10.1002/ijc.30754.

13.

Breast cancer incidence trends in Norway and estimates of overdiagnosis.

van Luijt PA, Heijnsdijk EA, van Ravesteyn NT, Hofvind S, de Koning HJ.

J Med Screen. 2017 Jun;24(2):83-91. doi: 10.1177/0969141316668379. Epub 2016 Oct 17.

PMID:
27754936
14.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

15.

Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.

Arrospide A, Rue M, van Ravesteyn NT, Comas M, Soto-Gordoa M, Sarriugarte G, Mar J.

BMC Cancer. 2016 Jun 1;16:344. doi: 10.1186/s12885-016-2386-y.

16.

Extrapolation of pre-screening trends: Impact of assumptions on overdiagnosis estimates by mammographic screening.

Ripping TM, Verbeek AL, Ten Haaf K, van Ravesteyn NT, Broeders MJ.

Cancer Epidemiol. 2016 Jun;42:147-53. doi: 10.1016/j.canep.2016.04.015. Epub 2016 May 3.

17.

Reply to Koleva-Kolarova et al.

de Koning HJ, Alagoz O, Schechter CB, van Ravesteyn NT.

Breast. 2016 Jun;27:182-3. doi: 10.1016/j.breast.2016.01.005. Epub 2016 Mar 2. No abstract available.

PMID:
26946960
18.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

19.

Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study.

Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, Kerlikowske K, Fenton JJ, Melnikow J, de Koning HJ, Hubbard RA.

Ann Intern Med. 2016 Feb 16;164(4):205-14. doi: 10.7326/M15-1241. Epub 2016 Jan 12.

20.

Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation.

Arrospide A, Rue M, van Ravesteyn NT, Comas M, Larrañaga N, Sarriugarte G, Mar J.

BMC Cancer. 2015 Oct 12;15:671. doi: 10.1186/s12885-015-1700-4.

21.

Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ.

J Natl Cancer Inst. 2015 May 6;107(7). pii: djv103. doi: 10.1093/jnci/djv103. Print 2015 Jul.

22.

Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.

Sankatsing VD, Heijnsdijk EA, van Luijt PA, van Ravesteyn NT, Fracheboud J, de Koning HJ.

Int J Cancer. 2015 Oct 15;137(8):1990-9. doi: 10.1002/ijc.29572. Epub 2015 May 8.

23.

Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program.

van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ.

Am J Prev Med. 2015 May;48(5):535-42. doi: 10.1016/j.amepre.2014.11.010.

24.

Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in The Netherlands.

Ripping TM, Verbeek AL, Fracheboud J, de Koning HJ, van Ravesteyn NT, Broeders MJ.

Int J Cancer. 2015 Aug 15;137(4):921-9. doi: 10.1002/ijc.29452. Epub 2015 Feb 5.

25.

Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN.

Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.

26.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

27.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

28.

Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.

Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS.

J Natl Cancer Inst. 2014 May 28;106(6):dju092. doi: 10.1093/jnci/dju092. Print 2014 Jun.

29.

Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control.

Mandelblatt JS, Tosteson AN, van Ravesteyn NT.

JAMA Intern Med. 2013 Feb 11;173(3):227-8. doi: 10.1001/jamainternmed.2013.2127. No abstract available.

30.

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality.

Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS.

Breast Cancer Res Treat. 2012 Dec;136(3):823-35. doi: 10.1007/s10549-012-2274-3. Epub 2012 Oct 27.

31.

The population and high-risk approaches to prevention: quantitative estimates of their contribution to population health in the Netherlands, 1970-2010.

Mackenbach JP, Lingsma HF, van Ravesteyn NT, Kamphuis CB.

Eur J Public Health. 2013 Dec;23(6):909-15. doi: 10.1093/eurpub/cks106. Epub 2012 Aug 8.

PMID:
22878901
32.

Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis.

Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL.

Ann Intern Med. 2012 May 1;156(9):635-48. doi: 10.7326/0003-4819-156-9-201205010-00006. Review.

33.

Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.

van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ.

Ann Intern Med. 2012 May 1;156(9):609-17. doi: 10.7326/0003-4819-156-9-201205010-00002.

34.

Modeling the impact of population screening on breast cancer mortality in the United States.

Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ.

Breast. 2011 Oct;20 Suppl 3:S75-81. doi: 10.1016/S0960-9776(11)70299-5.

35.

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals.

van Ravesteyn NT, Heijnsdijk EA, Draisma G, de Koning HJ.

Br J Cancer. 2011 Sep 27;105(7):1082-8. doi: 10.1038/bjc.2011.300. Epub 2011 Aug 23.

36.

Interpreting overdiagnosis estimates in population-based mammography screening.

de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ.

Epidemiol Rev. 2011;33:111-21. doi: 10.1093/epirev/mxr009. Epub 2011 Jun 27. Review.

37.

More on screening mammography.

van Ravesteyn NT, Heijnsdijk EA, de Koning HJ.

N Engl J Med. 2011 Jan 20;364(3):282-3; author reply 285-6. doi: 10.1056/NEJMc1011881. No abstract available.

PMID:
21247323
38.

Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States.

van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):112-22. doi: 10.1158/1055-9965.EPI-10-0944. Epub 2010 Nov 30.

39.

Measuring mobility limitations in children with cerebral palsy: content and construct validity of a mobility questionnaire (MobQues).

van Ravesteyn NT, Scholtes VA, Becher JG, Roorda LD, Verschuren O, Dallmeijer AJ.

Dev Med Child Neurol. 2010 Oct;52(10):e229-35. doi: 10.1111/j.1469-8749.2010.03729.x. Epub 2010 Jul 14.

40.

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2009 Nov 17;151(10):738-47. doi: 10.7326/0003-4819-151-10-200911170-00010. Erratum in: Ann Intern Med. 2010 Jan 19;152(2):136.

41.

Measuring mobility limitations in children with cerebral palsy: interrater and intrarater reliability of a mobility questionnaire (MobQues).

Van Ravesteyn NT, Dallmeijer AJ, Scholtes VA, Roorda LD, Becher JG.

Dev Med Child Neurol. 2010 Feb;52(2):194-9. doi: 10.1111/j.1469-8749.2009.03341.x. Epub 2009 Sep 11.

Supplemental Content

Loading ...
Support Center